JP2003512028A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003512028A5 JP2003512028A5 JP2001530364A JP2001530364A JP2003512028A5 JP 2003512028 A5 JP2003512028 A5 JP 2003512028A5 JP 2001530364 A JP2001530364 A JP 2001530364A JP 2001530364 A JP2001530364 A JP 2001530364A JP 2003512028 A5 JP2003512028 A5 JP 2003512028A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- ccx ckr
- polynucleotide
- binding
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108700036632 Atypical chemokine receptor 4 Proteins 0.000 description 20
- 101100490183 Mus musculus Ackr4 gene Proteins 0.000 description 20
- 102100034065 Atypical chemokine receptor 4 Human genes 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 18
- 229920001184 polypeptide Polymers 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- 108091033319 polynucleotide Proteins 0.000 description 13
- 239000002157 polynucleotide Substances 0.000 description 13
- 102000040430 polynucleotide Human genes 0.000 description 13
- 230000027455 binding Effects 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 102000019034 Chemokines Human genes 0.000 description 6
- 108010012236 Chemokines Proteins 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 102100036842 C-C motif chemokine 19 Human genes 0.000 description 4
- 102100021933 C-C motif chemokine 25 Human genes 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102100036846 C-C motif chemokine 21 Human genes 0.000 description 1
- 102100021936 C-C motif chemokine 27 Human genes 0.000 description 1
- 101710112538 C-C motif chemokine 27 Proteins 0.000 description 1
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 230000033300 receptor internalization Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15901599P | 1999-10-12 | 1999-10-12 | |
| US60/159,015 | 1999-10-12 | ||
| US15921099P | 1999-10-13 | 1999-10-13 | |
| US60/159,210 | 1999-10-13 | ||
| US17297999P | 1999-12-20 | 1999-12-20 | |
| US60/172,979 | 1999-12-20 | ||
| US17338999P | 1999-12-28 | 1999-12-28 | |
| US60/173,389 | 1999-12-28 | ||
| US18662600P | 2000-03-03 | 2000-03-03 | |
| US60/186,626 | 2000-03-03 | ||
| PCT/US2000/028067 WO2001027146A2 (en) | 1999-10-12 | 2000-10-10 | Chemokine receptor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003512028A JP2003512028A (ja) | 2003-04-02 |
| JP2003512028A5 true JP2003512028A5 (enExample) | 2007-10-18 |
| JP4754143B2 JP4754143B2 (ja) | 2011-08-24 |
Family
ID=27538581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001530364A Expired - Fee Related JP4754143B2 (ja) | 1999-10-12 | 2000-10-10 | ケモカインレセプター |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1224222B1 (enExample) |
| JP (1) | JP4754143B2 (enExample) |
| AT (1) | ATE457317T1 (enExample) |
| AU (1) | AU783776B2 (enExample) |
| CA (1) | CA2387018C (enExample) |
| DE (1) | DE60043823D1 (enExample) |
| DK (1) | DK1224222T3 (enExample) |
| ES (1) | ES2339326T3 (enExample) |
| WO (1) | WO2001027146A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE39849E1 (en) | 1999-10-12 | 2007-09-18 | Chemocentryx, Inc. | Methods for identifying modulators of CCX CKR activity |
| US6835547B1 (en) | 1999-10-12 | 2004-12-28 | Chemocentryx, Inc. | Methods for identifying modulators of CCX CKR activity |
| WO2001066598A2 (en) * | 2000-03-03 | 2001-09-13 | Icos Corporation | Chemoattractant receptor characterization and cell selection materials and methods and chemokine receptor ccr11 materials and methods |
| AU2003250221A1 (en) * | 2002-08-19 | 2004-03-11 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 6(cxcr6) |
| US20050176073A1 (en) * | 2004-02-06 | 2005-08-11 | Chemocentryx, Inc. | Cell proliferation associated with CCX CKR expression |
| US20050208595A1 (en) * | 2004-03-19 | 2005-09-22 | Brown Arthur M | High throughput assay systems and methods for identifying agents that alter expression of cellular proteins |
| CN100342017C (zh) | 2004-05-10 | 2007-10-10 | 中国医学科学院肿瘤医院肿瘤研究所 | 基因重组趋化抗原疫苗 |
| US9718887B2 (en) | 2012-09-06 | 2017-08-01 | Adelaide Research & Innovation Pty Ltd | Methods and products for preventing and/or treating metastatic cancer |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US5055556A (en) | 1981-10-06 | 1991-10-08 | The Board Of Trustees Of The Leland Stanford Jr. Univ. | Fluorescent conjugates for analysis of molecules and cells |
| US5093245A (en) | 1988-01-26 | 1992-03-03 | Applied Biosystems | Labeling by simultaneous ligation and restriction |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JPH02307059A (ja) | 1989-05-23 | 1990-12-20 | Seiko Instr Inc | 反応容器 |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| GB2273932A (en) | 1992-11-24 | 1994-07-06 | Stiefel Laboratories | Stable oligonucleotides |
| US5514555A (en) | 1993-03-12 | 1996-05-07 | Center For Blood Research, Inc. | Assays and therapeutic methods based on lymphocyte chemoattractants |
| US5563762A (en) | 1994-11-28 | 1996-10-08 | Northern Telecom Limited | Capacitor for an integrated circuit and method of formation thereof, and a method of adding on-chip capacitors to an integrated circuit |
| EP0899332A3 (en) * | 1997-08-15 | 2000-07-05 | Smithkline Beecham Corporation | The G-protein coupled receptor HFIAO41 |
| US5932445A (en) * | 1997-11-07 | 1999-08-03 | Incyte Pharmaceuticals, Inc. | Signal peptide-containing proteins |
| JP2002241399A (ja) * | 1997-12-24 | 2002-08-28 | Asahi Kasei Corp | ７回膜貫通型受容体蛋白質ｅｔ２４０ |
| WO1999052945A2 (en) * | 1998-04-16 | 1999-10-21 | Millenium Pharmaceuticals, Inc. | NOVEL MOLECULES OF THE BGCKr-RELATED PROTEIN FAMILY AND USES THEREOF |
| WO2000026369A1 (en) * | 1998-11-04 | 2000-05-11 | Chiron Corporation | Isolated vshk-1 receptor polypeptides and methods of use thereof |
| US6620615B1 (en) * | 1999-04-23 | 2003-09-16 | Curagen Corporation | G-protein coupled receptor—encoding nucleic acids |
| US9715915B2 (en) | 2014-10-30 | 2017-07-25 | Samsung Electronics Co., Ltd. | Magneto-resistive devices including a free layer having different magnetic properties during operations |
-
2000
- 2000-10-10 AU AU11959/01A patent/AU783776B2/en not_active Ceased
- 2000-10-10 DK DK00973455.9T patent/DK1224222T3/da active
- 2000-10-10 WO PCT/US2000/028067 patent/WO2001027146A2/en not_active Ceased
- 2000-10-10 DE DE60043823T patent/DE60043823D1/de not_active Expired - Lifetime
- 2000-10-10 AT AT00973455T patent/ATE457317T1/de not_active IP Right Cessation
- 2000-10-10 JP JP2001530364A patent/JP4754143B2/ja not_active Expired - Fee Related
- 2000-10-10 ES ES00973455T patent/ES2339326T3/es not_active Expired - Lifetime
- 2000-10-10 EP EP00973455A patent/EP1224222B1/en not_active Expired - Lifetime
- 2000-10-10 CA CA002387018A patent/CA2387018C/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Brannan et al. | The product of the H19 gene may function as an RNA | |
| Cheng et al. | Identification of potential target genes for Adr1p through characterization of essential nucleotides in UAS1 | |
| JP2005538696A5 (enExample) | ||
| WO2022179349A1 (zh) | 新型冠状病毒抗原及其应用 | |
| CA2362527A1 (en) | A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer | |
| JP2003512028A5 (enExample) | ||
| JP2021104046A (ja) | ホルムアルデヒドを含有する液体系細胞診用保存剤中検体から核酸を単離する方法 | |
| US20180312921A1 (en) | Process and kit for determining in vitro the immune status of an individual | |
| EP3978510A1 (en) | Norovirus-binding peptide | |
| JP2005511023A5 (enExample) | ||
| WO2023184616A1 (zh) | 一种克隆tcr序列的检测方法及其应用 | |
| EP2573169B1 (en) | Cartilage-specific hif-2 transgenic mouse as an animal model for arthritis, and use thereof | |
| Briat et al. | Tau factor from Escherichia coli mediates accurate and efficient termination of transcription at the bacteriophage T3 early termination site in vitro | |
| JP7410480B2 (ja) | がんにおける融合遺伝子 | |
| EP2554672A1 (en) | Nucleic acid structure, method for producing complex using same, and screening method | |
| CN106102772B (zh) | 用于预防和/或治疗与dennd1a变体2相关疾病的组合物和方法 | |
| WO2025045078A1 (zh) | 一种用于调控rna甲基化修饰的编辑系统及其应用 | |
| JP2004097213A (ja) | 核酸および／またはタンパク質の選択方法 | |
| US20240352452A1 (en) | Crispr-based protein barcoding and surface assembly | |
| EP1929042A2 (en) | Detection of mutations in a gene associated with resistance to viral infection, oas2 or oas3 | |
| CN104761639B (zh) | scFv抗体、其编码基因及其在制备治疗或预防乙肝制剂中的应用 | |
| CN113699157B (zh) | Pd-l1核酸适配体、其筛选方法及应用 | |
| KR101658135B1 (ko) | 혈액 응고인자 ⅷ 유전자를 타겟으로 하는 엔도뉴클레아제 및 이의 용도 | |
| EP3978511A1 (en) | Norovirus-binding peptide | |
| EP3995506A1 (en) | Norovirus-binding peptide |